SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools reported FY2025 revenue of $85.3 million, down 6%…

STANDARD BIOTOOLS INC. · 8-K filed Feb 24, 2026 at 16:15 ET

At the news

BEARISHIMPACT 7/10

8-K filed Feb 24, 2026 at 16:15 ET

Standard BioTools reported FY2025 revenue of $85.3 million, down 6% YoY, with Q4 revenue of $23.8 million, down 4% YoY. While net loss improved to $58.8 million (from $90.9 million) due to a one-time $38.4 million tax benefit, core operating performance declined. The company expects FY2026 revenue of $80-$85 million, signaling continued contraction. Despite $550 million in cash from the SomaLogic sale, the fundamental business is weakening.

  • FY2025 revenue was $85.3 million, down 6% YoY; Q4 revenue was $23.8 million, down 4% YoY
  • FY2025 net loss improved to $58.8 million from $90.9 million in 2024, but this was primarily due to a one-time $38.4 million tax benefit, not operational improvement
  • Adjusted EBITDA loss was $62.6 million in 2025, only a 3% improvement from $64.2 million in 2024
  • The company guided FY2026 revenue to $80-$85 million, indicating an expectation of continued revenue decline

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access